Cancer Family
Malignant Endocrine Neoplasm
CI-CAN-00000230Explore in graph →
576 active trials16 approved drugs58 evidence items
- NCIt
- C3575
Loading cancer entity…
Cancer Family
CI-CAN-00000230Explore in graph →
Clinical trials
1,801 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (238)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01121939 | Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | completed | Phase 2 | 43 | SCRI Development Innovations, LLCOTHER | 1 | Feb 5, 2016 | clinicaltrials |
| NCT01900951 | Temozolomide as Maintenance Therapy in Small Cell Lung Cancer | unknown | Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00401609 |
| G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients(G-Step) |
| completed |
| Phase 1 / Phase 2 |
| 85 |
| National Cancer Institute, NaplesOTHER |
| 1 |
| Jan 14, 2016 |
| clinicaltrials |
| NCT01533181 | Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 2 | Jan 14, 2016 | clinicaltrials |
| NCT00299390 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer | terminated | Phase 2 | 10 | BayerINDUSTRY | 0 | Dec 31, 2015 | clinicaltrials |
| NCT01159327 | Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy | terminated | Phase 2 | 13 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 11, 2015 | clinicaltrials |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
| NCT01713296 | Pazopanib in Relapsed and Refractory Small Cell Lung Cancer | completed | Phase 2 | 58 | Hellenic Oncology Research GroupOTHER | 1 | Oct 8, 2015 | clinicaltrials |
| NCT00755157 | Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | University Hospital of CreteOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01421316 | Hair-sparing Whole Brain Radiotherapy | terminated | Phase 2 | 29 | University Hospital, GhentOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00217633 | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer | completed | Phase 2 | 38 | Gynecologic Oncology GroupNETWORK | 2 | May 29, 2015 | clinicaltrials |
| NCT00316186 | First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin | completed | Phase 2 | 33 | GlaxoSmithKlineINDUSTRY | 2 | May 7, 2015 | clinicaltrials |
| NCT00470054 | Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00521144 | Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00469469 | Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma | withdrawn | Phase 2 | 0 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT01500720 | Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer | completed | Phase 2 | 179 | SanofiINDUSTRY | 16 | Apr 13, 2015 | clinicaltrials |
| NCT02409849 | Octreotide LAR as Maintenance Treatment for Patients With NEC | unknown | Phase 2 | 92 | Peking UniversityOTHER | 1 | Apr 7, 2015 | clinicaltrials |
| NCT00831844 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 3 | Mar 30, 2015 | clinicaltrials |
| NCT00759824 | A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide | completed | Phase 2 | 64 | European Lung Cancer Working PartyOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT01886287 | P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 12, 2015 | clinicaltrials |
| NCT02323737 | Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer | completed | Phase 2 | 62 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 30, 2014 | clinicaltrials |
| NCT00131911 | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2014 | clinicaltrials |
| NCT00359359 | A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 26 | BayerINDUSTRY | 1 | Nov 4, 2014 | clinicaltrials |
| NCT02262897 | The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer | unknown | Phase 2 | 40 | Tongji UniversityOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT00912392 | Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC) | completed | Phase 2 | 138 | Shandong Simcere-Medgenn Bio-pharmaceutical Co., LtdINDUSTRY | 1 | Sep 3, 2014 | clinicaltrials |
| NCT00134043 | Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2014 | clinicaltrials |
| NCT00118235 | Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2014 | clinicaltrials |
| NCT00098813 | Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00084487 | Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00182689 | Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00066742 | Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT00079040 | Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00773955 | R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | May 12, 2014 | clinicaltrials |
| NCT00848016 | Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 7, 2014 | clinicaltrials |
| NCT00778817 | IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2014 | clinicaltrials |
| NCT00616109 | Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC | completed | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 21, 2014 | clinicaltrials |
| NCT00086827 | Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2014 | clinicaltrials |
| NCT02038738 | 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | unknown | Phase 1 / Phase 2 | 250 | Ochsner Health SystemOTHER | 1 | Jan 17, 2014 | clinicaltrials |
| NCT02039518 | Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients | unknown | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Jan 17, 2014 | clinicaltrials |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2014 | clinicaltrials |
| NCT00052949 | Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer | completed | Phase 2 | 91 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00607113 | Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00002608 | Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | completed | Phase 2 | 30 | Ottawa Regional Cancer CentreOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00004922 | Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00452634 | Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC) | completed | Phase 2 | 62 | National Cancer Center, KoreaOTHER_GOV | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01872416 | A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer | unknown | Phase 2 | 30 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00075439 | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Feb 5, 2016source: clinicaltrials